Oneness Biotech Co., Ltd. Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (2008)

Organization Overview

First Clinical Trial
2020
NCT05059509
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Oneness Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

centella asiatica (2 trials)

plectranthus amboinicus (2 trials)

Drugs in Phase 2 Trials (2)

fb704a (1 trial)

fb825 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4